The liquid form of the vaccine is changed into an aerosol using a nebulizer. It can then be inhaled through the mouth using the nebulizer machine. According to CanSino, the vaccine can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath.
On September 4, 2022, China’s National Medical Products Administration approved CanSino's Ad5-nCoV for emergency use as a booster vaccine, which is the world's first inhaled Covid-19 vaccine mist. The needle-free vaccines that could be highly appealing to vaccine-hesitant people can also be self-administered. The announcement pushed the company’s shares up as much as 14.5 percent Monday morning in Hong Kong
The vaccine mist is named Convidecia Air. The liquid form of the vaccine is changed into an aerosol using a nebulizer. It can then be inhaled through the mouth using the nebulizer machine. According to CanSino, the vaccine can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath. CanSino received the approval of its clinical trial application for the vaccine in March 2021. According to studies published in The Lancet, Convidecua Air can 'induce strong humoral, cellular and mucosal immunity to achieve triple protection and effectively contain the infection and spread of the virus.'
Chinese scientists published a pre-print study in July which revealed that people who received one booster dose of CanSino's inhaled vaccine after two doses of the inactivated jab from Chinese maker Sinovac developed more antibodies than people who received three Sinovac shots. A month after receiving the inhaled booster, 92.5 percent of people had developed neutralizing antibodies for Omicron. Meanwhile, those who had three doses of Sinovac's jab did not demonstrate any neutralizing antibodies for Omicron, either four weeks or six months after getting a booster.
CanSino's booster vaccine is reported to be an inhaled version of the one-shot adenovirus Covid-19 jab that the company developed in partnership with the Chinese military-run Academy of Military Medical Sciences. According to Fortune, the first jab proved to be 66 percent effective in preventing infection and 92 percent effective against severe disease in early clinical trials. It was the first in the world to undergo human testing in March 2020 and has been used in China, Mexico, Pakistan, Malaysia, and Hungary after being rolled out in February 2021.